Background: The World Health Organization drug-resistant tuberculosis (DR-TB) 2016 guidelines reclassified para-aminosalicylic acid (PAS) as Group D3 "add-on" drug. We studied our DR-TB data wherein PAS was widely and preferably used as a substitute in the standardized regimen in varied situations and report its utility in DR-TB.
Methodology: This retrospective observational study enrolled both pulmonary and extrapulmonary DR-TB patients receiving PAS in the programmatic management of DR-TB from March 2012 to June 2013. They were divided into seven subgroups on the basis of indication for PAS substitution in the standardized regimen for DR-TB cases. The clinical profile and outcomes were analyzed.
Results: PAS was substituted in 250 cases (225 - pulmonary DR-TB and 25 - extrapulmonary DR-TB). PAS was used in (1) pre-extensively drug-resistant TB (XDR-TB) fluoroquinolones (FQs) - 136 (54.4%), (2) XDR-TB - 15 (6%), (3) substitute drug for serious adverse events - 3 (1.2%), (4) pregnant DR-TB patients - 5 (2%), (5) patients on successful private-based second-line therapy adopted under the Revised National Tuberculosis Control Program - 10 (4%), (6) substitute drug for previous FQ exposure - 5 (2%), and (7) Category V - 76 (30.4%). Although 51.2% had an unfavorable response (UFR) against 48.8% with FR, wide disparity was noted in subgroups. FR was observed in 68.4% pre-XDR-TB (FQ), 80% pregnant patients, 90% adopted from private on successful second-line therapy, 80% previous FQ exposure against 40% XDR-TB, 7.9% Category V, and 0% PAS substitution for adverse drug reactions (ADRs). UFR was seen in 31.6% pre-XDR-TB (FQ), 20% pregnant patients, 10% adopted from private on successful second-line therapy, 20% of previous FQ exposure against 60% XDR-TB, 92.1% Category V, and 100% on PAS substitution for ADR.
Conclusion: In view of the safety and efficacy of PAS in our DR-TB patients except for XDR and Category V group, we recommend larger studies with PAS and consider its reclassification into Group C rather than Group D3.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219125 | PMC |
| http://dx.doi.org/10.4103/lungindia.lungindia_141_18 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mapping Drug-Resistant Tuberculosis Treatment Outcomes in Hunan Province, China.
Trop Med Infect Dis
December 2024
School of Population Health, Faculty of Health Sciences, Curtin University, Perth, WA 6102, Australia.
Background: Drug-resistant tuberculosis (DR-TB) remains a major public health challenge in China, with varying treatment outcomes across different regions. Understanding the spatial distribution of DR-TB treatment outcomes is crucial for targeted interventions to improve treatment success in high-burden areas such as Hunan Province. This study aimed to map the spatial distribution of DR-TB treatment outcomes at a local level and identify sociodemographic and environmental factors associated with poor treatment outcomes in Hunan Province, China.
View Article and Find Full Text PDFNavigating DR-TB Treatment care: a qualitative exploration of barriers and facilitators to retention in care among people with history of early disengagement from drug-resistant tuberculosis treatment in Johannesburg, South Africa.
BMC Health Serv Res
January 2025
HIV and Other Infectious Diseases Research Unit (HIDRU), South African Medical Research Council: CAPRISA-MRC HIV-TB Pathogenesis and Treatment Research Unit, Free State, South Africa.
Background: Despite advances in drug-resistant tuberculosis (DR-TB) diagnosis, treatment, and service delivery, individuals with DR-TB often face significant socioeconomic and psychosocial challenges due to limited resources. These challenges can hinder retention in care, undermining the progress made in DR-TB management. As a consequence, advances in DR-TB diagnostics and treatment have not resulted in DR-TB programs meeting the 75% treatment success targets set by the World Health Organization (WHO).
View Article and Find Full Text PDFBackground: Drug-resistant TB (DR-TB) remains a public health concern in Kenya, with an estimated 2,500 individuals acquiring DR-TB annually. Despite significant progress in DR-TB management, the treatment success rate (TSR) in 2021 stood at 77%, falling short of the 85% target. This low TSR occurs amidst a complex range of treatment challenges, including psychosocial factors.
View Article and Find Full Text PDFEstimating the Early Transmission Inhibition of new treatment regimens for drug-resistant tuberculosis.
J Infect Dis
January 2025
Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA, United States.
Introduction: Most drug-resistant tuberculosis (DR-TB) occurs due to transmission of unsuspected or ineffectively treated DR-TB. The duration of treatment to stop person-to-person spread of DR-TB is uncertain. We evaluated the impact of novel regimens, including BPaL, on DR-TB transmission using the human-to-guinea pig (H-GP) transmission model.
View Article and Find Full Text PDFDrug-Resistant Tuberculosis in Rural Eastern Cape, South Africa: A Study of Patients' Characteristics in Selected Healthcare Facilities.
Int J Environ Res Public Health
November 2024
Department of Laboratory Medicine and Pathology, Walter Sisulu University, Private Bag X5117, Mthatha 5099, South Africa.
This study investigated the characteristics and outcomes of drug-resistant tuberculosis patients in selected rural healthcare facilities in the Eastern Cape, South Africa. A retrospective review of clinical records from 456 patients, covering the period from January 2018 to December 2020, revealed a statistically significant relationship between DR-TB types and age groups (Chi-square statistic: 30.74, -value: 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!